Promoting Maternal and Infant Survival Everywhere (PROMISE)
Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID)
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Protocol Summary: 1077BF is a research protocol designed to address in an integrated and comprehensive fashion three critical questions currently facing HIV-infected pregnancy and postpartum women and their infants:
- What is the optimal intervention for the prevention of antipartum and intrapartum transmission of HIV?
- What is the optimal intervention for the prevention of postpartum transmission in breastfeeding (BF) infants?
- What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child transmission ends (either at delivery or cessation of BF)?
PROMISE seeks to examine effective methods of preventing transmission of HIV from mother-to-child during pregnancy, labor and delivery, and breastfeeding. This is one component of the three-part PROMISE study that is being conducted at various sites in Africa and other parts of the world where women typically receive a short course of HAART during pregnancy and where breastfeeding is common.
Years: 2011 – present
Investigator: Tsungai Chipato, MBChB, FRCOG, MCE
Locations: Parirenyatwa, Seke North, and St. Mary’s CRSs
Fowler MG, Qin M, Fiscus SA, Currier JS, et al (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737.
Comments are closed.